CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV
Abstract Background Chemokines/cytokines play important roles in the pathogenesis of chronic hepatitis C (CHC). However, their clinical characteristics and implications in treatment responses to pegylated interferon plus ribavirin treatment (PegIFN/RBV) have not been fully illustrated yet. In this s...
Main Authors: | Chia-Chen Lin, Shih-Huan Su, Wen-Juei Jeng, Chien-Hao Huang, Wei Teng, Wei-Ting Chen, Yi-Cheng Chen, Chun-Yen Lin, I-Shyan Sheen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-12-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12876-017-0724-4 |
Similar Items
-
Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients
by: Ying-Chieh Chen, et al.
Published: (2019-08-01) -
Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.
by: Hanan H Rizk, et al.
Published: (2016-01-01) -
Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
by: Yu Zhang, et al.
Published: (2016-01-01) -
Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
by: Kamil Grubczak, et al.
Published: (2021-07-01) -
Gene expression pattern of CCL2, CCL3, and CXCL8 in patients with bipolar disorder
by: Mohsen Ghoryani, et al.
Published: (2019-01-01)